Following the value decrease of the Lifecare (LIFE-ME) share at Oslo Stock
Exchange/Merkur Market Monday 12 October 2020 the company has received questions
from shareholders and wants to clarify: 

There are no changes in relation to Lifecare’s patented core sensor technology,
Sencell, either alone or in relation to our partners Digital Diagnostics AG or
the project FORGETDIABETES. 

On the 3rd of October 2020, Lifecare announced that FORGETDIABETES received EUR
3.9 million, just over NOK 43 million, from a FET-Proactive announcement for
development of a bionic invisible pancreas under the EU funding programme for
research and innovation, Horizon 2020. The funds are partitioned on the seven
parties in Italy, Germany and France, where Lifecare received EUR 570,000, close
to NOK 6.3 million.

On the 25th of August 2020, Lifecare announced that Digital Diagnostics had
received approval for clinical tests related to the Cantisense rapid test for
Covid-19, from the Federal Institute for Drugs and Medical Devices (BfArM) in
Germany. Digital Diagnostics have informed Lifecare that the clinical trials
originally expected to be finalized in October 2020, are delayed due to delays
in the set-up of the device production. The clinical trials are expected to take
place early 2021.  

About Lifecare
Lifecare (LIFE-ME) is a Bergen-based technology company developing a miniature
sensor for correct and continuous monitoring of diabetics’ blood sugar. Its
patented technology is also used as a central component in a rapid test for
Covid-19 and as a measurement unit for reading out different biomarkers.

For more information, please contact:
Joacim Holter
CEO, Lifecare
joacim.holter@lifecare.no
+47 40 05 90 40